{"entity":{"id":"nct07011719","kind":"trial","name":"Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma","aka":[],"tldr":"A phase 3 trial of Cabozantinib in renal cell carcinoma, run by Arcus Biosciences, Inc., now recruiting.","summary":"Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma is a phase 3 interventional study registered as NCT07011719 by Arcus Biosciences, Inc., with 720 participants planned, started 2025-09-08 and due to reach its primary completion in 2028-04. Interventions recorded: Casdatifan, Cabozantinib, Placebo. Conditions listed: Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07011719","url":"https://clinicaltrials.gov/study/NCT07011719"}],"tags":["ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["cabozantinib"],"companies":["arcus-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07011719","phase":"3","setting":"A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma","sponsor":"Arcus Biosciences, Inc.","enrolled":720,"outcomes":[]},"route":"/trials/nct07011719/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/"}],"company":[{"id":"arcus-biosciences","kind":"company","name":"Arcus Biosciences","route":"/companies/arcus-biosciences/"}]}}